key: cord-0929479-nqshwt2o
authors: Miller, Jonathan; Yan, Kelley S.
title: COVID-19 gastrointestinal symptoms and attenuation of the immune response to SARS-CoV-2
date: 2021-03-19
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.03.029
sha: 2704cafbe56ecbe8b687d2ce7eea0a6a2a21f07b
doc_id: 929479
cord_uid: nqshwt2o

nan

As we eclipse year one of the SARS-CoV-2 pandemic, our understanding of this virus is only beginning to unfold despite an exponentially growing body of literature. Early descriptions of the novel respiratory illness COVID-19 were quickly followed by reports of a multi-system disease 1 . Gastrointestinal (GI) symptoms are frequently reported in COVID-19 patients, which raised questions of gut infection and the possibility of fecaloral transmission. Indeed, viral RNA was detected in stool of infected patients by qRT-PCR, which frequently remained positive beyond the duration of positivity of their nasopharyngeal samples [2] [3] [4] . Multiple groups have reported GI epithelial co-expression of the host receptor ACE2 and TMPRSS2, a protease enabling cell entry through cleavage of the eponymous spike protein [5] [6] [7] [8] . In line with the susceptibility of the GI epithelium to SARS-CoV-2 entry, viral RNA by in situ hybridization 9 and viral nucleocapsid protein (NP) by immunofluorescence (IF) have been detected in infected patient intestinal biopsies 2 while viral particles have been demonstrated by transmission electron microscopy (TEM) 9 . Moreover, recent studies using ex vivo enteroid or organoid models convincingly demonstrated that GI epithelium is permissive to SARS-CoV-2 infection 6, [9] [10] [11] . Notably, human intestinal enteroids inoculated with the virus or nasopharyngeal aspirates from infected patients showed intracellular NP and increasing viral titers over time, indicating productive viral replication within intestinal epithelium [9] [10] [11] . Enteroids also exhibited double-stranded RNA, a requisite intermediate produced during patients with immunologic changes within the GI tract on histologic, transcriptomic, and proteomic levels. 12 The authors analyzed endoscopic biopsy specimens from COVID-19-afflicted patients, finding no gross abnormalities when compared with matched controls 12 . While they found ACE2 diffusely expressed throughout the GI tract, viral NP was found more prominently in the ileum versus duodenum in the limited number of specimens studied 12 . They attribute this to increased MUC2+ goblet cell prevalence in distal small intestine which colocalized with NP immunostaining, and their TEM images showing viral particles present primarily in exit vesicles of goblet cells 12 . This may corroborate findings from bronchial air-liquid interface cultures demonstrating tropism for goblet cells 13 but were nevertheless surprising given relatively low ACE2 expression in intestinal goblet cell clusters 5 , evidence of goblet cell depletion in an infected patient's colonic biopsies 9 , and data from human intestinal organoids demonstrating enterocytes were susceptible to infection whereas goblet cells were not 6, 11 . Livanos et al. also find evidence of NP staining in a non-goblet crypt-base cell population but do not discern this population as Paneth, stem cells, or another population 12 . This raises additional questions of cellular tropism and host entry determinants because enterocytes in the villus compartment express the highest levels of ACE2.

The authors also performed mass cytometry (CyTOF) immunophenotypic analysis of endoscopic biopsies and blood samples from these patients 12 Data are limited, but these restraints are understandable given the prudent restrictions on non-urgent endoscopic procedures on COVID-19 patients implemented by many hospitals during the pandemic.

Livanos et al. also correlated COVID-19 patients with GI symptoms of diarrhea, nausea, or vomiting at the time of hospital admission with nearly 50% reduced odds of severe disease or mortality when compared to patients without GI symptoms 12 . Similar analysis applied to an independent Italian cohort found patients with diarrhea had significantly reduced rates of mortality or ICU admission 12 . While the authors attribute this to immunomodulation, perhaps these patients differed in other ways as well (e.g., presented earlier due to more troubling or obvious GI symptoms). The authors partially dispel this explanation, reporting that rates of respiratory symptoms and oxygen requirement were similar regardless of GI symptoms and few patients overall had mild disease. They also found no difference in nasopharyngeal viral loads to explain these disparate outcomes 12 . In support of an altered immune response in GI patients, they analyzed levels of circulating cytokines and found that those with GI symptoms had lower levels of IL-6 and IL-8, among other cytokines associated with poor outcomes in COVID-19 12, 14, 15 .

In its totality, this study identifies less severe clinical outcomes in COVID-19 patients with GI symptoms across multiple cohorts, in agreement with prior studies 16, 17 . The authors attribute this observation to an attenuated immune response related to COVID-19 involvement of the GI tract. It is known that type III interferons (IFNs) are important for mucosal immunity and induce less systemic inflammation and tissue destruction compared with type I IFNs 18 . Absence of IFN III in a genetically deficient colon epithelial line culture resulted in dramatically increased SARS-CoV-2 replication 19 . A skew toward type III IFN was J o u r n a l P r e -p r o o f demonstrated in enteroids infected with SARS-CoV-2 11 , and may explain the plausible link between mucosal immune regulation and systemic viral sequelae. In the lung, type III IFNs are more prevalent in lower airways, participate in mucosal injury along with type I IFNs and may impair epithelial regeneration 20, 21 . Further studies will need to investigate if similar effects occur in intestinal epithelium as Livanos et al. found increased type I and II IFNs in the epithelium despite no evidence of gross or histologic injury and downregulation of various cytokines in serum 12 .

Major questions remain regarding how SARS-CoV-2 behaves in the GI tract, including the viability of the SARS-CoV-2 viral envelope in the harsh biochemical environment of the GI lumen 6 . Other questions include interaction of the virus with disease states that modify susceptibility including potential infection via susceptible metaplastic cells in the esophagus, thus bypassing the gastric acidity or bile emulsification in those patients with Barrett's esophagus 22 . The rapid global spread of this virus has required equally rapid dissemination of biomedical information, but we are hopefully now witnessing the shift toward more rigorous study of SARS-CoV-2. Moving forward, as new variants arise and the population becomes increasingly vaccinated, interplay of the virus, GI epithelium, and the immune system will remain a topic of great interest to potentially inform novel anti-viral therapeutics or development of an oral vaccine strategy. 

Extrapulmonary manifestations of COVID-19

Evidence for Gastrointestinal Infection of SARS-CoV-2

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

SARS-CoV-2 productively infects human gut enterocytes

Infection of bat and human intestinal organoids by SARS-CoV-2

Intestinal host response to SARS-CoV-2 infection and COVID-19 outcomes in patients with gastrointestinal symptoms

Goblet Cell Hyperplasia Increases SARS-CoV-2 Infection in COPD

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

An inflammatory cytokine signature predicts COVID-19 severity and survival

Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States

COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in

Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Type III interferons disrupt the lung epithelial barrier upon viral recognition

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

Tropism of SARS-CoV-2 for Barrett's Esophagus may Increase Susceptibility to Developing COVID-19